Einschluss und Ausschlusskriterien im Vorfeld zur multimodalen Therapie der Peritonealkarzinose
|
include – exclude |
Discuss in tumor board |
|
|
Tumortype |
||
|
Appendiceal tumor |
in |
|
|
Colorectal cancer |
in |
|
|
Gastric cancer primary |
in |
|
|
Gastric cancer recurrent |
ex |
|
|
Pancreatic cancer |
ex |
|
|
Ovarian cancer recurrent |
in |
|
|
Ovarian cancer primary |
discuss |
|
|
Primary peritoneal carcinoma |
in |
|
|
Peritoneal mesothelioma |
in |
|
|
Rare primary or secondary tumours of the peritoneum |
discuss |
|
|
Tumorstage |
||
|
Mesenteric and/or paraaortal lymph node involvement |
ex |
|
|
Extraabdominal metastases |
ex |
|
|
Liver metastases |
ex |
discuss for colorectal cancer |
|
Clinical parameters |
||
|
Ileus |
ex |
|
|
Renal insufficiency |
ex |
|
|
More than 2 previous therapeutic approaches |
discuss |
|
|
Age > 70 |
discuss |
|
|
Pulmonary and cardiovascular disorders |
discuss (plus anaesthesiologist and internal specialist) |
Survival rate of subgroups of patients with positive prognostic factors after CRS and IPHC /EPIC
|
Primary tumour |
Selection criteria |
Survival rate |
Author |
|
|
Gastric |
Limited extent of PC (P1) |
8 yrs |
55 % |
Fujimoto |
|
Gastric |
Optimal CRS |
2 yrs |
45 % |
Hall |
|
Colorectal |
Limited PC and diffuse PC/ small nodules (<5mm) Optimal CRS |
5 yrs 5yrs |
25 % 22% |
Glehen |
|
Colorectal |
Optimal CRS |
5 yrs |
43 % |
Verwaal |
|
Colorectal |
Optimal CRS |
5 yrs |
37 % |
Shen |
|
Recurrent |
Optimal CRS |
5 yrs |
42 % |
Cotte |
PC = peritoneal carcinomatosis
CRS = cytoreductive surgery